Search

Displaying results 5651 - 5660 of 10000 in total
  1. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  2. Drug

    Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

    go.drugbank.com/drugs/DB15813
    Investigational

    Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins … , modify artificial antigen presenting cells (aAPC), and activate T-cells.

  3. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  4. Drug

    Decoquinate

    go.drugbank.com/drugs/DB11394
    ExperimentalVet approved

    Decoquinate is used in veterinary to delay the growth and reproduction of coccidian parasites.

  5. Drug

    Recombinant Cholera Toxin B Subunit

    go.drugbank.com/drugs/DB11643
    ApprovedInvestigational

    Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

  6. Drug

    Ferrimannitol ovalbumin

    go.drugbank.com/drugs/DB15824
    Investigational

    Ferrimannitol-ovalbumin (FMOA) is an adduct between ovalbumin and the complex Fe(III)-mannitol.

  7. Drug

    Yttrium Y-90

    go.drugbank.com/drugs/DB13076
    ApprovedInvestigational

    Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.

  8. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the

  9. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  10. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.